- Home
- / Invitrocue
Invitrocue
Revenue
$540 K
FY, 2019
Invitrocue Summary
Company Summary
- Overview
- Invitrocue is a life sciences company that specializes in developing 3D cell-based models derived from liver and tumour tissues. Its Onco-PDO technology enables patient-derived cancer cells to be cultured in laboratories for testing against a panel of drugs to support personalised clinical decisions.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Singapore, SG | view all locations
- Website
- https://www.invitrocue.com/
- Cybersecurity rating
Table of Contents
Key People
Andreas Lindner, CEO of Europe AG, Director
Martin Bach, Vice President, Operations
Susan Chia, General Manager of Singapore
LocationsView all
7 locations detected
Singapore HQ
Singapore
11 Biopolis Way, Helios
Sydney, NSW
Australia
level 2/350 Kent St
SP
Brazil
R. Natividade, 139 - Vila Nova Conceição
Su Zhou Shi, Jiang Su Sheng
China
Ruo Shui Lu
München, BY
Germany
Hildegardstraße 9
New Territories
Hong Kong
No. 11, Biotech Centre 2, 11 Science Park W Ave, Sha Tin
Invitrocue Financials
Summary Financials
- Revenue (FY, 2019)
- $540.0K
- Gross profit (FY, 2019)
- $486.0K
- Net income (FY, 2019)
- ($6.7M)
- Cash (FY, 2019)
- $361.0K
- EBIT (FY, 2019)
- ($6.6M)